Table 3.
Univariate Analysis for Subject Characteristics with HER2 Expression
| Over Expression |
Normal | Chi-square (p.value) |
|
|---|---|---|---|
| Age | 0.659 | ||
| Early onset (<50) | 2 (3.4%) | 13 (22.4%) | |
| Late onset (>50) | 4 (6.9%) | 39 (67.2%) | |
| Sex | 0.293 | ||
| Male | 1 (1.7%) | 20 (34.5%) | |
| Female | 5 (8.6%) | 32 (55.2%) | |
| Histologic | 0.862 | ||
| Adenocarcinoma | 5 (8.6%) | 46 (79.3%) | |
| Mucinous Adenocarcinoma |
1 (1.7%) | 4 (6.9%) | |
| Signet Ring Cell | 0 | 1 (1.7%) | |
| Neuroendocrine | 0 | 1 (1.7%) | |
| Grade | 0.789 | ||
| Well Diff | 4 (6.9%) | 33 (56.9%) | |
| Moderately Diff | 0 | 7 (12.1%) | |
| Poorly Diff | 1 (1.7%) | 6 (10.3% | |
| Specific | 1 (1.7%) | 6 (10.3% | |
| Tumor location | 0.291 | ||
| Colon | 1 (1.7%) | 20 (34.5%) | |
| Rectum | 5 (8.6%) | 32 (55.2%) | |
| Stage | 0.001 | ||
| I | 0 | 1 (1.7%) | |
| II | 5 (8.6%) | 7 (12.1%) | |
| III | 0 | 17 (29.3%) | |
| IV | 1 (1.7%) | 27 (46.6%) | |
| NRAS | 0.829 | ||
| Wild type | 5 (8.6%) | 45 (77.6%) | |
| Mutation | 1 (1.7%) | 7 (12.1%) |